Condition: Relapsed Refractory Acute Lymphoblastic Leukemia · Sponsor: King Faisal Specialist Hospital & Research Center
This is a Phase Ia, open label, dose finding single center trial designed to evaluate the maximum tolerated dose, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of CD19 CAR T cells targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in adults (age 18 - 75) with relapsed/refractory acute lymphoblastic leukemia (ALL).
This description comes directly from the study's public registry record.
Riad El Fakih · 00966539056287 · relfakih1@kfshrc.edu.sa
Always discuss trial participation with your own doctor first.
| King Faisal Specialist Hospital and Research Center | Riyadh, Riyadh Region, Saudi Arabia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07361029